文献速递胸部肿瘤头颈与中枢神经肿瘤

晚期及转移性非小细胞肺癌的基因组改变与脑转移发生率:系统综述与Meta分析

Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Thorac Oncol · 2023-06-29

该系统综述与Meta分析纳入64篇文献,汇总晚期及转移性NSCLC患者诊断时脑转移患病率及每年新发脑转移发生率,并按EGFR、ALK、KRAS等基因组改变分层。结果显示诊断时合并脑转移的总患病率为28.6%,ALK阳性(34.9%)或RET重排(32.2%)患者最高;中位随访24个月时,野生型组每年新发脑转移发生率为0.13,EGFR组0.16,ALK组0.17,KRAS组0.10,ROS1组0.13,RET组0.12。

要点

  • 诊断时脑转移总患病率为28.6%(45项研究,95%CI 26.1-31.0)。
  • ALK阳性(34.9%)或RET重排(32.2%)患者诊断时脑转移患病率最高。
  • 中位随访24个月,ALK组每年新发脑转移发生率0.17,EGFR组0.16,野生型组0.13。

核心结论

  • Meta分析表明,携带某些可靶向基因组改变的患者脑转移患病率和发生率更高,支持在分期和随访时进行脑影像检查,并需要具有脑穿透性的靶向治疗。

研究设计与样本

  • 系统综述与Meta分析,符合PRISMA,PROSPERO注册号CRD42022315915,检索MEDLINE、EMBASE和Cochrane Library 2000年1月至2022年5月发表的文章。
  • 共纳入64篇独特文章,其中45项研究提供24,784例NSCLC患者的患病率数据,40项研究提供9,058例NSCLC患者的发生率数据。
  • 采用随机效应模型计算合并发生率。

主要发现

  • 诊断时合并脑转移的合并患病率为28.6%(45项研究,95%CI 26.1-31.0)。
  • 诊断时脑转移患病率在ALK阳性患者中为34.9%,在RET重排患者中为32.2%。
  • 中位随访24个月,每年新发脑转移发生率在野生型组为0.13(14项研究,95%CI 0.11-0.16),EGFR组为0.16(16项研究,95%CI 0.11-0.21),ALK组为0.17(5项研究,95%CI 0.10-0.27),KRAS组为0.10(4项研究,95%CI 0.06-0.17),ROS1组为0.13(3项研究,95%CI 0.06-0.28),RET组为0.12(2项研究,95%CI 0.08-0.17)。

临床怎么用

  • 作者认为,该结果支持在分期和随访时进行脑影像检查,并需要具有脑穿透性的靶向治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Brain metastases (BMs) in patients with advanced and metastatic NSCLC are linked to poor prognosis. Identifying genomic alterations associated with BM development could influence screening and determine targeted treatment. We aimed to establish prevalence and incidence in these groups, stratified by genomic alterations. METHODS: A systematic review and meta-analysis compliant with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses were conducted (PROSPERO identification CRD42022315915). Articles published in MEDLINE, EMBASE, and Cochrane Library between January 2000 and May 2022 were included. Prevalence at diagnosis and incidence of new BM per year were obtained, including patients with EGFR, ALK, KRAS, and other alterations. Pooled incidence rates were calculated using random effects models. RESULTS: A total of 64 unique articles were included (24,784 patients with NSCLC with prevalence data from 45 studies and 9058 patients with NSCLC having incidence data from 40 studies). Pooled BM prevalence at diagnosis was 28.6% (45 studies, 95% confidence interval [CI]: 26.1-31.0), and highest in patients that are ALK-positive (34.9%) or with RET-translocations (32.2%). With a median follow-up of 24 months, the per-year incidence of new BM was 0.13 in the wild-type group (14 studies, 95% CI: 0.11-0.16). Incidence was 0.16 in the EGFR group (16 studies, 95% CI: 0.11-0.21), 0.17 in the ALK group (five studies, 95% CI: 0.10-0.27), 0.10 in the KRAS group (four studies, 95% CI: 0.06-0.17), 0.13 in the ROS1 group (three studies, 95% CI: 0.06-0.28), and 0.12 in the RET group (two studies, 95% CI: 0.08-0.17). CONCLUSIONS: Comprehensive meta-analysis indicates a higher prevalence and incidence of BM in patients with certain targetable genomic alterations. This supports brain imaging at staging and follow-up, and the need for targeted therapies with brain penetrance.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gillespie CS, Mustafa MA, Richardson GE, et al. Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2023. PMID: 37392903. doi:10.1016/j.jtho.2023.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。